First CPAnet symposium identifies four key research areas for chronic pulmonary aspergillosis
Thu, 11/16/2017 - 15:40News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 16, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news
ImmunoPET: the future of lung scans in aspergillosis?
Wed, 11/15/2017 - 11:48News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 15, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news
Vitamin D deficiency and aspergillosis
Mon, 11/06/2017 - 17:31News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 6, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news
Hologic to retain CEO MacMillan | Personnel Moves – November 3, 2017
Hologic (NSDQ:HOLX) said this week its current prez and CEO Stephen MacMillan will stay on with the company, resolving rumors that he may depart it to take up the corner office at Zimmer Biomet (NYSE:ZBH).
In an SEC filing, the Marlborough, Mass.-based company’s board said it approved a special “performance-based retention equity grant” to MacMillan after he had begun to receive interest from other medical device firms.
“Mr. MacMillan has led a dramatic turnaround of Hologic since joining in December 2013. The company’s performance has increased significantly under his leadership and he perso...
Source: Mass Device - November 3, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News ConMed Corp. Hologic Invacare kentimaging Meritech Capital Partners Pulmatrix Inc. Sanofi-Aventis Smith & Nephew Tissue Regenix zimmerbiomet Source Type: news
Did Ötzi the Iceman have aspergillosis?
Wed, 10/25/2017 - 12:46News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 25, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news
Chronic Pulmonary Aspergillosis IV
Monday, October 16, 2017 - 08:36Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 16, 2017 Category: Respiratory Medicine Authors: ROrritt Source Type: news
Chronic Pulmonary Aspergillosis III
Monday, October 16, 2017 - 08:35Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 16, 2017 Category: Respiratory Medicine Authors: ROrritt Source Type: news
Chronic Pulmonary Aspergillosis II
Monday, October 16, 2017 - 08:34Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 16, 2017 Category: Respiratory Medicine Authors: ROrritt Source Type: news
Chronic Pulmonary Aspergillosis I
Monday, October 16, 2017 - 08:32Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 16, 2017 Category: Respiratory Medicine Authors: ROrritt Source Type: news
Efficacy of ambruticin analogs in a murine model of invasive pulmonary aspergillosis
Ambruticins are a family of polyketides. The antifungal activity of an ambruticin,KOSN-2079, was tested in the mouse model of invasive aspergillosis.KOSN-2079 significantly reduced pulmonary fungal burdens and improved survival over that with the vehicle control. These results support the continued development of ambruticins as antifungal agents. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 11, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news
Efficacy of the investigational echinocandin ASP9726 in a guinea pig model of invasive pulmonary aspergillosis
ASP9726 is an investigational echinocandin with in vitro activity against Aspergillus species. We evaluated the pharmacokinetics and efficacy of this agent in an established guinea pig model of invasive pulmonary aspergillosis.ASP9726 plasma concentrations were measured in guinea pigs administered either a single dose or multiple doses of this agent at 2.5, 5, and 10 mg/kg of body weight/day by subcutaneous injection. Immunosuppressed guinea pigs were inoculated with A. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 10, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news
Researchers help develop new antifungal drug
(University of Liverpool) University researchers, working with F2G Limited (Eccles, Manchester), have developed a new antifungal drug to help in the treatment of life threatening invasive fungal infections such as invasive aspergillosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 6, 2017 Category: International Medicine & Public Health Source Type: news
8th Advances Against Aspergillosis: scholarship application deadline
Date: Wednesday, September 20, 2017Year: 2018Location: Lisbon, PortugalContent-type: current_conferences (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - September 20, 2017 Category: Respiratory Medicine Authors: GAtherton Source Type: news
8th Advances Against Aspergillosis: abstract submissions deadline
Date: Wednesday, September 20, 2017Year: 2018Location: Lisbon, Portugal.Content-type: current_conferences (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - September 20, 2017 Category: Respiratory Medicine Authors: GAtherton Source Type: news
Management of allergic and chronic pulmonary aspergillosis: part 3
(Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - September 19, 2017 Category: Respiratory Medicine Authors: GAtherton Source Type: news
